1] Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA. [2] Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts, USA. [3] Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. [4].
Nat Genet. 2013 Nov;45(11):1380-5. doi: 10.1038/ng.2794. Epub 2013 Oct 6.
Genome sequencing can identify individuals in the general population who harbor rare coding variants in genes for Mendelian disorders and who may consequently have increased disease risk. Previous studies of rare variants in phenotypically extreme individuals display ascertainment bias and may demonstrate inflated effect-size estimates. We sequenced seven genes for maturity-onset diabetes of the young (MODY) in well-phenotyped population samples (n = 4,003). We filtered rare variants according to two prediction criteria for disease-causing mutations: reported previously in MODY or satisfying stringent de novo thresholds (rare, conserved and protein damaging). Approximately 1.5% and 0.5% of randomly selected individuals from the Framingham and Jackson Heart Studies, respectively, carry variants from these two classes. However, the vast majority of carriers remain euglycemic through middle age. Accurate estimates of variant effect sizes from population-based sequencing are needed to avoid falsely predicting a substantial fraction of individuals as being at risk for MODY or other Mendelian diseases.
基因组测序可以鉴定出一般人群中携带孟德尔疾病相关基因罕见编码变异的个体,这些个体可能因此具有更高的疾病风险。之前对表型极端个体的罕见变异的研究存在选择偏倚,可能会导致高估效应大小估计值。我们对表现良好的人群样本(n=4003)中的七个与青年发病的成年型糖尿病(MODY)相关的基因进行了测序。我们根据两种疾病致病突变的预测标准对罕见变异进行了筛选:先前在 MODY 中报道过的或满足严格的新生突变阈值(罕见、保守和蛋白破坏性)的变异。分别来自弗雷明汉和杰克逊心脏研究的随机选择的个体中,约有 1.5%和 0.5%携带这两类变异。然而,绝大多数携带者在中年时仍保持血糖正常。需要从基于人群的测序中获得准确的变异效应大小估计值,以避免错误地预测很大一部分个体存在 MODY 或其他孟德尔疾病的风险。